Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2010

Open Access 01-12-2010 | Research

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Authors: Kenneth F Schulz, Douglas G Altman, David Moher, the CONSORT Group

Published in: Trials | Issue 1/2010

Login to get access

Abstract

The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience.
To encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will also be published in the Lancet, Obstetrics and Gynecology, PLoS Medicine, Annals of Internal Medicine, Open Medicine, Journal of Clinical Epidemiology, BMC Medicine, and Trials.
Appendix
Available only for authorised users
Literature
1.
Jüni P, Altman DG, Egger M: Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001, 323: 42-6. 10.1136/bmj.323.7303.42.CrossRefPubMedPubMedCentral
2.
Chan AW, Altman DG: Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005, 365: 1159-62. 10.1016/S0140-6736(05)71879-1.CrossRefPubMed
3.
Glasziou P, Meats E, Heneghan C, Shepperd S: What is missing from descriptions of treatment in trials and reviews?. BMJ. 2008, 336: 1472-4. 10.1136/bmj.39590.732037.47.CrossRefPubMedPubMedCentral
4.
Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E, Easterbrook PJ, Von Elm E, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR: Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE. 2008, 3: e3081-10.1371/journal.pone.0003081.CrossRefPubMedPubMedCentral
5.
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996, 276: 637-9. 10.1001/jama.276.8.637.CrossRefPubMed
6.
Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001, 357: 1191-4. 10.1016/S0140-6736(00)04337-3.CrossRefPubMed
7.
Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001, 134: 657-62.CrossRefPubMed
8.
Moher D, Schulz KF, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001, 285: 1987-91. 10.1001/jama.285.15.1987.CrossRefPubMed
9.
Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury : Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006, 185: 263-7.PubMed
10.
Hopewell S, Dutton S, Yu L-M, Chan A-W, Altman DG: The quality of reports of randomised trials in 2000 and 2006: a comparative study of articles indexed by PubMed. BMJ. 2010, 340: c723-10.1136/bmj.c723.CrossRefPubMedPubMedCentral
11.
12.
Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ: Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006, 295: 1152-60. 10.1001/jama.295.10.1152.CrossRefPubMed
13.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ: CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c869-10.1136/bmj.c869.CrossRefPubMedPubMedCentral
14.
Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995, 273: 408-12. 10.1001/jama.273.5.408.CrossRefPubMed
15.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998, 352: 609-13. 10.1016/S0140-6736(98)01085-X.CrossRefPubMed
16.
Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339: b2535-10.1136/bmj.b2535.CrossRefPubMedPubMedCentral
17.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, Standards for Reporting of Diagnostic Accuracy: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003, 326: 41-4. 10.1136/bmj.326.7379.41.CrossRefPubMedPubMedCentral
18.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, for the STROBE Initiative: Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007, 335: 806-8. 10.1136/bmj.39335.541782.AD.CrossRefPubMedPubMedCentral
19.
Standards of Reporting Trials Group: A proposal for structured reporting of randomized controlled trials. JAMA. 1994, 272: 1926-31. 10.1001/jama.272.24.1926.CrossRef
20.
Rennie D: Reporting randomized controlled trials. An experiment and a call for responses from readers. JAMA. 1995, 273: 1054-5. 10.1001/jama.273.13.1054.CrossRefPubMed
21.
Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, CONSORT Group: CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008, 371: 281-3. 10.1016/S0140-6736(07)61835-2.CrossRefPubMed
22.
Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG: Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004, 291: 2457-65. 10.1001/jama.291.20.2457.CrossRefPubMed
23.
Sackett DL: Commentary: Measuring the success of blinding in RCTs: don't, must, can't or needn't?. Int J Epidemiol. 2007, 36: 664-5. 10.1093/ije/dym088.CrossRefPubMed
24.
Schulz KF, Grimes DA: Blinding in randomised trials: hiding who got what. Lancet. 2002, 359: 696-700. 10.1016/S0140-6736(02)07816-9.CrossRefPubMed
25.
Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schünemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH: Randomized trials stopped early for benefit: a systematic review. JAMA. 2005, 294: 2203-9. 10.1001/jama.294.17.2203.CrossRefPubMed
26.
27.
Nuovo J, Melnikow J, Chang D: Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA. 2002, 287: 2813-4. 10.1001/jama.287.21.2813.CrossRefPubMed
28.
Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, CONSORT Group: Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004, 141: 781-8.CrossRefPubMed
29.
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Weyden Van Der MB: International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet. 2004, 364: 911-2. 10.1016/S0140-6736(04)17034-7.CrossRefPubMed
30.
Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003, 326: 1167-70. 10.1136/bmj.326.7400.1167.CrossRefPubMedPubMedCentral
31.
Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF, CONSORT Group: CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008, 5: e20-10.1371/journal.pmed.0050020.CrossRefPubMedPubMedCentral
32.
Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P: Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008, 148: 295-309.CrossRefPubMed
33.
Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C: Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006, 144: 364-7.CrossRefPubMed
34.
Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D, CONSORT group: Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008, 11 (337): a2390-10.1136/bmj.a2390.CrossRef
Metadata
Title
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Authors
Kenneth F Schulz
Douglas G Altman
David Moher
the CONSORT Group
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Trials / Issue 1/2010
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-11-32

Other articles of this Issue 1/2010

Trials 1/2010 Go to the issue

Study protocol

Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer - a randomized controlled trial

Study protocol

Dementia in residential care: education intervention trial (DIRECT); protocol for a randomised controlled trial

Study protocol

A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: Design and statistical methods of the PERSEUS clinical program

Study protocol

Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial

Research

Interaction between drug and placebo effects: a cross-over balanced placebo design trial

Study protocol

Development of an awareness-based intervention to enhance quality of life in severe dementia: trial platform